Synonyms: ALX-0600 | Gattex® | GLP2-2G | Revestive®
teduglutide is an approved drug (FDA and EMA (2012))
Compound class:
Peptide
Comment: Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue in which position 2 amino acid alanine is replaced by glycine, increasing the peptide's resistance to proteolytic cleavage by dipeptidyl peptidase-4 (DPP-4) [2]. The chemical structure shown here was generated using the SMILES from PubChem CID 16139605. The intestinotrophic effects of GLP-2 (e.g. promotion of intestinal growth, reduced epithelial cell apoptosis and inflammation) has led to the development of GLP-2 analogues like teduglutide for the treatment of GI disorders such as short bowel syndrome and inflammatory bowel diseases.
|
|
No information available. |
Summary of Clinical Use ![]() |
Teduglutide is used in the treatment of short bowel syndrome [2,5]. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Teduglutide is believed to promote mucosal growth and restore gastric emptying and secretion [2], via activation of the glucagon-like peptide 2 receptor (GLP2R). |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |